all report title image

ANTISENSE OLIGONUCLEOTIDES MARKET ANALYSIS

Antisense Oligonucleotides Market, by Drugs (Pegaptanib, Eteplirsen, Mipomersen, and Others), By Therapeutic Application (Cancer, Diabetes, Ocular Diseases, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy, Hemorrhagic Fever Viruses, HIV/AIDS, Cytomegalovirus Retinitis, and Others), by Distribution Channel (Hospitals, Retail Pharmacies, and Online Pharmacies), by Region (North America, Europe, Latin America, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Dec 2024
  • Code : CMI1879
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Challenges And Opportunities

Antisense Oligonucleotides Market Drivers:-

One of the major factors driving growth of the global antisense oligonucleotides market is increasing number of launches pertaining to novel Antisense Oligonucleotides products by key players in the market. For instance, in 2015, Exiqon A/S acquired by Qiagen launched new LNA Antisense Oligonucleotide GapmeRs. LNA Antisense Oligonucleotide GapmeRs is used for inactivation of RNA in functional analysis. Antisense LNA is an alternative to existing siRNAs. LNA Antisense Oligonucleotide are designed using advanced bioinformatics algorithm, which is combined with LNA (locked nucleic acid).

Furthermore, mergers and acquisitions by key players, in order to enhance their product offerings is expected to be a major driver for global antisense oligonucleotides market growth. For instance, in February 2018, Takeda Pharmaceuticals Company Ltd.—a pharmaceutical company—merged with Wave Life Sciences Ltd., which is involved in nuclei acid therapeutics. Takeda Pharmaceuticals has merged with Wave Life Sciences Ltd. to develop antisense oligonucleotides for central nervous system disorder, which includes Lou Gehrig’s disease, Frontotemporal dementia (FTD), Spinocerebellar ataxia type 3 (SCA3), and huntington’s disease. Lou Gehrig’s disease is also called as Amyotrophic lateral sclerosis (ALS). This acquisition will also help Takeda in gaining market share.

Robust pipeline is also another factor aiding in growth of the global market. For instance, in 2016 Ionis Pharmaceuticals completed phase 2 clinical trials of its ISIS CRP Rx. ISIS 329993 is an antisense oligonucleotide, which targets CRP (C reactive protein) in patients with paroxysmal atrial fibrillation. In 2015, Achieve Life Sciences completed Phase 2 clinical trials of its OGX 427. OGX 427 is used to treat castration resistant prostate cancer.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.